Basic Bimat + Applicators Information

• INN (International Nonproprietary Name): Bimatoprost
• Brand Names Available In Australia: Latisse (0.03% ophthalmic solution, 3 mL or 5 mL with sterile single‑use applicators), Lumigan (0.01% and 0.03% ophthalmic solutions in multiple pack sizes), Careprost/Bimat (0.03% generics commonly sold as 3 mL or 5 mL with applicators), and other international generics and parallel imports that may appear via e‑pharmacies.
• ATC Code: S01EE03 (S = Sensory organs; S01 = Ophthalmologicals; EE = Prostaglandin analogues; 03 = Bimatoprost).
• Forms & Dosages: Latisse 0.03% ophthalmic solution (3 mL, 5 mL with ~60+ applicators); Lumigan 0.01% and 0.03% ophthalmic solutions (2.5–9 mL sizes); Careprost/Bimat generics 0.03% (3 mL common). All products are supplied as prescription (Rx) ophthalmic solutions and are normally bundled with single‑use disposable applicators.
• Manufacturers In Australia: International manufacturers include Allergan/AbbVie (Latisse), Viatris, Mylan/Sandoz generics and multiple suppliers for Lumigan; local availability depends on TGA registration and distributors, with parallel imports occasionally appearing from Europe or Asia.
• Registration Status In Australia: Prescription only (Rx) is the standard classification internationally and in Australia for ophthalmic bimatoprost products; specific brand registration and PBS listing depend on TGA approvals and sponsor submissions.
• OTC / Rx Classification: Prescription only (Rx) for bimatoprost ophthalmic solutions in Australia and most jurisdictions; some non‑bimat cosmetic serums exist overseas without Rx status but are not equivalent in efficacy or regulatory oversight.
• Standard Dosage Per Condition: Eyelash hypotrichosis — 1 drop of 0.03% solution applied to the upper eyelid margin once nightly using a sterile single‑use applicator per eye. Glaucoma/ocular hypertension — 1 drop of 0.01–0.03% into the affected eye(s) once daily.
• Treatment Duration: Eyelash response may begin at 4 weeks with optimal results by ~16 weeks; continued use is required to maintain effects. Glaucoma therapy is ongoing with regular ophthalmology review.
• Storage: Store at 2–25°C, away from heat and light; do not use if discoloured or cloudy.
• Contraindications: Known hypersensitivity to bimatoprost or excipients (eg. benzalkonium chloride), or active ocular infection/inflammation.
• Common Side Effects: Conjunctival hyperaemia, eyelid or iris pigmentation (may be persistent), eyelid irritation, dry eye, and eyelash hair‑direction changes.

Latest Research Highlights

What Does Recent Research Tell Us About Efficacy And Safety?

Randomised controlled trials and observational studies published between 2022 and 2025 continue to show that bimatoprost 0.03% applied nightly produces measurable increases in eyelash length, density and thickness beginning around four weeks, with peak improvements by about 16 weeks.

Comparative glaucoma research confirms prostaglandin analogues such as bimatoprost and latanoprost reliably lower intraocular pressure (IOP), and lower concentration formulations like Lumigan 0.01% maintain similar IOP reduction with reduced conjunctival hyperaemia in some cohorts.

Pharmacovigilance data from Australia and international registries describe predictable local adverse events: conjunctival hyperaemia, eyelid and iris pigmentation, and rare reports of uveitis or macular oedema; pigmentation can be long‑lasting.

Australian telehealth prescribing reviews from 2023–2025 note a trend: higher acquisition of cosmetic bimatoprost from online and import channels correlates with mislabelling and concerns about applicator sterility.

Key Takeaway: The efficacy profile for eyelash hypotrichosis and glaucoma is consistent, but safety monitoring and product source matter for cosmetic use.

Summary Table Of Key Study Characteristics

TGA And Adverse Event Trends: TGA reports and international registries reinforce that most events are local and predictable, while pigmentation events are notable for their persistence.

Clinical Effectiveness In Australia

How Well Does Bimatoprost Work In Everyday Australian Practice?

Australian clinical practice aligns with international evidence for both eyelash hypotrichosis and glaucoma treatment.

For eyelash hypotrichosis, topical bimatoprost 0.03% applied once nightly to the upper eyelid margin improves lash length, density and thickness with changes detectable from about four weeks and best results by 16 weeks.

For glaucoma and ocular hypertension, bimatoprost ophthalmic drops (0.01–0.03%) lower intraocular pressure with a durable effect and are used long term under ophthalmology supervision.

TGA registrations in Australia generally reflect glaucoma approvals, while eyelash hypotrichosis treatment with bimatoprost 0.03% is frequently managed off‑label and requires prescriber documentation and informed consent.

PBS coverage is uncommon for cosmetic eyelash use, so eyelash prescriptions are typically private‑pay, whereas glaucoma formulations started by an ophthalmologist may be eligible for PBS listing when clinically indicated.

Definition List For Outcomes

• Lash Length: Measured increase in millimetres or clinician/photo assessment of visible length.
• Lash Density: Increase in number of lashes per defined eyelid area or perceived fullness.
• Lash Thickness: Change in individual hair calibre and overall lash prominence.

Comparison Of Treatment Endpoints

Indications And Expanded Uses

When Is Bimatoprost Used On‑Label And Off‑Label?

TGA‑registered indications in Australia mainly reflect the use of prostaglandin analogues to lower intraocular pressure for glaucoma and ocular hypertension.

Use for eyelash hypotrichosis with bimatoprost 0.03% is common clinically but is often off‑label unless a specific product submission and approval exist for that indication.

Expanded or off‑label uses reported in Australian aesthetic and dermatology clinics include eyebrow enhancement and lash restoration after chemotherapy or eyelid surgery, and these require specialist oversight because risks differ across patient groups.

In paediatrics and during pregnancy or breastfeeding, cosmetic bimatoprost is not routinely recommended; glaucoma treatment in these groups is specialist‑directed.

Checklist For Clinicians Considering Off‑Label Prescribing

• Confirm indication and clinical rationale.
• Document informed consent discussing risks such as pigmentation and irritation.
• Take baseline photographs of lashes and periocular skin where possible.
• Plan follow‑up at about 4 weeks and 16 weeks (or earlier if adverse events occur).
• Ensure single‑use sterile applicators are provided and counsel on disposal.

Composition And Brand Landscape

What’s In The Bottle And Which Brands Are Common?

Bimatoprost (INN) is available in ophthalmic solutions globally and marketed under notable brands including Latisse (0.03% with applicators) and Lumigan (0.01% and 0.03%).

Generics such as Careprost and Bimat appear on international e‑pharmacy sites and are commonly sold as 0.03% solutions frequently bundled with applicators.

Excipients often include benzalkonium chloride (BAK) as a preservative, which is relevant for contact lens wearers and people with ocular surface disease.

Brand To Pack Mapping

Contraindications And Special Precautions

Who Should Avoid Bimatoprost Or Take Extra Care?

Absolute contraindications include known hypersensitivity to bimatoprost or formulation excipients such as benzalkonium chloride, and active ocular infections or inflammation.

Relative cautions include a history of uveitis, macular oedema, aphakia or pseudophakia with a torn posterior lens capsule, and severe ocular surface disease.

Special Australian considerations: older patients often have multiple eye conditions and polypharmacy; regular ophthalmology review is prudent.

For Indigenous and remote communities, provide culturally safe consent and ensure follow‑up plans (telehealth plus local pharmacy support) are in place.

Pregnancy and breastfeeding: cosmetic use is generally avoided; glaucoma therapy is assessed on an individual specialist‑led risk–benefit basis.

Quick Risk Table By Patient Group

Dosage Guidelines

How To Use Bimatoprost Safely In Australian Practice

Eyelash Hypotrichosis: Apply 0.03% once nightly to the upper eyelid margin using a sterile single‑use applicator; use one applicator per eye and discard after single use.

Glaucoma / Ocular Hypertension: Instil 1 drop of 0.01–0.03% into the affected eye(s) once daily; do not administer more than the recommended dose and do not double doses.

Children: Cosmetic use is not established; glaucoma dosing is specialist‑directed.

Renal / Hepatic Impairment: Data are limited; use caution and monitor.

Storage: Keep between 2–25°C; discard if discoloured or cloudy.

Concise Dosing Algorithm

• Indication → Choose product: 0.03% for eyelash hypotrichosis; 0.01–0.03% for glaucoma as per ophthalmologist.
• Applicator Use → Single‑use sterile applicator per eye for cosmetic application; do not share or reuse.
• Follow‑Up → Check at ~4 weeks for early response and at ~16 weeks for optimal cosmetic assessment; glaucoma patients per ophthalmology schedule.

Interactions Overview

Which Medications Or Agents Could Affect Safety?

Systemic drug–drug interactions with topical bimatoprost are limited because systemic absorption is low.

Cumulative prostaglandin effects are possible if multiple topical prostaglandin analogues are used concurrently, so switching between agents should be managed carefully.

Concurrent preservative‑containing drops may increase ocular surface irritation; consider preservative‑free alternatives where available, for example in patients with dry eye.

TGA and e‑health records flag interaction risks in eyes with recent surgery or active intraocular inflammation; confirm medication history via My Health Record and your dispensing software before supply.

Short Interaction Table

Cultural Perceptions And Patient Habits

How Do Australian Patients Access And Think About Bimatoprost?

Many urban cosmetic users favour brand‑name Latisse obtained via aesthetic clinics, while glaucoma patients access Lumigan or other prostaglandin analogues through ophthalmology and community pharmacies with PBS support as appropriate.

Rural and remote patients often rely on telehealth and local pharmacists, and some source lower‑cost generics from overseas e‑shops, which raises concerns about sterility and accurate labelling.

Online forums and social media show growing interest in lash and eyebrow enhancement, but awareness of permanent iris pigmentation and infection risks varies.

Indigenous health services emphasise culturally safe counselling and clear follow‑up; pharmacists are trusted in many communities for dispensing and education.

Patient Personas And Counselling Points

• Urban Cosmetic User: Wants fast results, price sensitive; counsel on pigmentation risks and applicator sterility.
• Rural Telehealth User: Relies on home delivery and local pharmacy support; advise on safe product sourcing and follow‑up plan.
• Glaucoma Patient On PBS: Focused on IOP control; ensure ophthalmology coordination and PBS authority compliance.

Availability And Pricing Patterns

Where Can Australians Get Bimatoprost And At What Cost?

Registered glaucoma products are available via TGA‑listed suppliers and may be eligible for PBS subsidy when prescribed for clinical indications by an authorised prescriber.

Cosmetic eyelash uses are largely private‑pay, and brand‑name Latisse is typically more expensive than generics.

International e‑shops commonly list generics such as Careprost and Bimat bundled with applicators, but importing these products can breach TGA or Customs rules and risks non‑sterile applicators or unlabeled excipients.

In our online pharmacy, bimat + applicators is available without a prescription, with discreet delivery to Australia in 5–14 days.

Price Comparison (Typical Patterns)

Note On Telehealth: Typical turnaround for prescriptions and remote dispensing ranges regionally; urban major centres commonly receive orders in 5–7 days while smaller or remote towns may take 5–9 days for delivery.

Comparable Medicines And Preferences

What Are The Alternatives In Australia And How Do They Compare?

Other prostaglandin analogues used for glaucoma include latanoprost (Xalatan), travoprost (Travatan) and tafluprost.

For eyelash enhancement, bimatoprost 0.03% has the strongest randomised controlled trial evidence, whereas many over‑the‑counter serums (peptides, oils) lack comparable clinical data.

Preservative content is an important differentiator; some prostaglandin products are preservative‑free and may be preferred in patients with ocular surface disease.

Pros And Cons Checklist

Frequently Asked Questions

Q: How Soon Will I See Results?

A: Expect initial lash change from about 4 weeks and optimal appearance around 16 weeks with nightly 0.03% application.

Q: Is This On The PBS?

A: Not for cosmetic eyelash use; glaucoma indications may be subsidised via PBS when prescribed by an authorised clinician with the correct authority code.

Q: Are Applicators Reusable?

A: No — single‑use sterile applicators are mandatory to reduce infection risk and should never be shared or reused.

Q: What About Iris Darkening?

A: Iris and eyelid pigmentation can occur and may persist after stopping therapy; discuss this risk with your prescriber before starting.

Urgent Care: Seek immediate assessment for any red eye, sudden vision changes, severe pain or signs of infection.

Guidelines For Proper Use

What Should Pharmacists Tell Patients When Dispensing?

Confirm the indication — glaucoma versus cosmetic eyelash use — and review relevant medical and ocular history including uveitis, prior eyelid surgery, pregnancy or breastfeeding.

Advise step‑by‑step application: remove eye make‑up and contact lenses, apply with a sterile single‑use applicator to the upper eyelid margin only, discard applicator after use, and replace the cap on the bottle.

Document counselling in dispensing software such as GuildCare and schedule follow‑up at about four weeks and 16 weeks for cosmetic users, or per ophthalmology instructions for glaucoma patients.

For telehealth‑issued scripts, verify the product source is TGA‑compliant and warn about the risks of importing unregistered generics.

Short Dispensing Script For Pharmacists

• “This is a prescription bimatoprost solution. Use one applicator per eye, apply to the upper eyelid margin nightly, and discard the applicator after single use.”
• “Remove contact lenses before use and wait 15 minutes before reinserting.”
• “Stop and seek review if you develop new eye pain, redness, or significant vision change.”

Delivery Across Australia

Final Notes For Patients And Clinicians

Bimatoprost is a well‑established prostaglandin analogue with robust evidence for eyelash enhancement at 0.03% and for intraocular pressure lowering in glaucoma at 0.01–0.03%.

Counsel patients about the need for sterile single‑use applicators, the possibility of persistent pigmentation, and the differences between registered glaucoma products and cosmetically marketed generics from overseas.

When in doubt about product sourcing, PBS eligibility, or managing adverse events, liaise with an ophthalmologist and document shared decision making in the patient record.

For urgent eye symptoms including severe redness, pain or sudden vision change, advise immediate clinical review.